AMLX Amylyx Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AMLX matters now
Amylyx Pharmaceuticals, Inc. (AMLX) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.77 with -3.32% on the session and $1.48B in market capitalization; recent performance reads 1-month +23.00% and YTD +29.72%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-41.3M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.3%.
The latest indexable market news headline is "Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $27.50; recent insider activity includes FONTEYNE PAUL R. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.34
P/S
0.00
EV/EBITDA
-7.31
DCF Value
$2.30
FCF Yield
-9.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.7%
ROA
-51.1%
ROIC
-57.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-41.3M | $-0.37 |
| Q4 2025 | $0.00 | $-33.0M | $-0.28 |
| FY 2025 | $0.00 | $-144.7M | $-1.53 |
| Q3 2025 | $0.00 | $-34.4M | $-0.37 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$27.50
Target (Median)
$27.50
Target Range
$21.00 - $34.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.16
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.